AssetMark Inc
EGRX

AssetMark Inc’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AssetMark Inc’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-106
Closed -$3.1K – 1724
2022
Q4 		$3.1K Hold
106
– – ﹤0.01% 1399
2022
Q3 		$3K Hold
106
– – ﹤0.01% 1369
2022
Q2 		$5K Buy
106
+60
+130% +$2.76K ﹤0.01% 1312
2022
Q1 		$2K Sell
46
-3
-6% -$144 ﹤0.01% 1453
2021
Q4 		$2K Buy
49
+1
+2% +$52 ﹤0.01% 1401
2021
Q3 		$3K Hold
48
– – ﹤0.01% 1244
2021
Q2 		$2K Buy
48
+17
+55% +$702 ﹤0.01% 1226
2021
Q1 		$1K Buy
31
+5
+19% +$232 ﹤0.01% 1313
2020
Q4 		$1K Sell
26
-20
-43% -$935 ﹤0.01% 1369
2020
Q3 		$2K Sell
46
-42
-48% -$1.84K ﹤0.01% 1170
2020
Q2 		$4K Sell
88
-2
-2% -$100 ﹤0.01% 994
2020
Q1 		$4K Sell
90
-5
-5% -$251 ﹤0.01% 1122
2019
Q4 		$6K Buy
95
+5
+6% +$298 ﹤0.01% 1088
2019
Q3 		$5K Buy
+90
New +$5.06K ﹤0.01% 1060
2018
Q1 		– Sell
-2
Closed – – 2067
2017
Q4 		$0 Sell
2
-52
-96% -$2.89K ﹤0.01% 2170
2017
Q3 		$3K Buy
54
+34
+170% +$2.06K ﹤0.01% 1239
2017
Q2 		$2K Buy
+20
New +$1.64K ﹤0.01% 1252

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

AssetMark Inc's EGRX Position: Q1 2023 in Review

AssetMark Inc sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 106 shares — an estimated $3.1K sold.

AssetMark Inc first reported a position in EGRX in Q2 2017 and held it in 17 quarters. The position peaked at $6K in Q4 2019. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • AssetMark Inc reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • AssetMark Inc sold 106 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.1K.
  • AssetMark Inc first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 17 quarters.
  • AssetMark Inc's Eagle Pharmaceuticals, Inc. position peaked at $6K in Q4 2019.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on AssetMark Inc's 13F filing for Q1 2023, filed 5 May 2023.